[go: up one dir, main page]

AR126963A1 - Agonistas de ahr - Google Patents

Agonistas de ahr

Info

Publication number
AR126963A1
AR126963A1 ARP220102376A ARP220102376A AR126963A1 AR 126963 A1 AR126963 A1 AR 126963A1 AR P220102376 A ARP220102376 A AR P220102376A AR P220102376 A ARP220102376 A AR P220102376A AR 126963 A1 AR126963 A1 AR 126963A1
Authority
AR
Argentina
Prior art keywords
patient
disease
alkyl
compound
compounds
Prior art date
Application number
ARP220102376A
Other languages
English (en)
Inventor
Cheryl Ann Clarke Christian Alexander Gernert Douglas Linn Green Steven James Holloway Willia Carson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR126963A1 publication Critical patent/AR126963A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a ciertos compuestos agonistas de AHR sustituidos, a composiciones farmacéuticas que comprenden los compuestos y a métodos de uso de los compuestos para tratar enfermedades inmunomediadas. Reivindicación 1: Un compuesto de la fórmula (1), en donde, R¹ se selecciona de fenilo, alquilo C₁-C₆, cicloalquilo C₃-C₆, heteroarilo de 5 a 6 miembros opcionalmente sustituido con 1 a 2 Rⁱ y heteroarilo bicíclico de 8 a 10 miembros opcionalmente sustituido con 1 a 2 Rⁱ; R² se selecciona de H y OH; X se selecciona del enlace, -C(R³)₂- y -C(R³)₂C(R³)₂-; Y se selecciona de -C(R³)₂-, -O- y -N(Rʲ)-; R³ se selecciona independientemente de H y alquilo C₁-C₃; Rⁱ se selecciona de halógeno, CH₃, OCH₃ y CF₃; Rʲ es alquilo C₁-C₃, o una sal farmacéuticamente aceptable de estos. Reivindicación 12: Un método para tratar una enfermedad inmunomediada en un paciente, que comprende administrar a un paciente que necesita de dicho tratamiento una cantidad eficaz de un compuesto de una cualquiera de las reivindicaciones 1 a 10, o la composición farmacéutica de la reivindicación 11. Reivindicación 13: Un método para tratar una enfermedad o trastorno seleccionado de psoriasis, colitis ulcerosa, enfermedad de Crohn, enfermedad de injerto contra huésped y esclerosis múltiple en un paciente, que comprende administrar a un paciente que necesita de dicho tratamiento una cantidad eficaz de un compuesto de una cualquiera de las reivindicaciones 1 a 10, o la composición farmacéutica de la reivindicación 11.
ARP220102376A 2021-09-13 2022-09-01 Agonistas de ahr AR126963A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163261129P 2021-09-13 2021-09-13

Publications (1)

Publication Number Publication Date
AR126963A1 true AR126963A1 (es) 2023-12-06

Family

ID=83508443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102376A AR126963A1 (es) 2021-09-13 2022-09-01 Agonistas de ahr

Country Status (11)

Country Link
US (1) US12037322B2 (es)
EP (1) EP4402126A1 (es)
JP (2) JP7748545B2 (es)
KR (1) KR20240056750A (es)
CN (1) CN118215654A (es)
AR (1) AR126963A1 (es)
AU (1) AU2022342091A1 (es)
CA (1) CA3231016A1 (es)
MX (1) MX2024003107A (es)
TW (1) TWI829325B (es)
WO (1) WO2023039278A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120225518A (zh) * 2022-11-15 2025-06-27 伊莱利利公司 Ahr激动剂
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2025240124A1 (en) 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120987908A (zh) * 2025-10-24 2025-11-21 上海泽德曼医药科技有限公司 具有吡啶酮结构的化合物及其在医药上的应用
CN121005656A (zh) * 2025-10-24 2025-11-25 上海泽德曼医药科技有限公司 一种具有吡啶酮结构的化合物及其在医药上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
DK1357111T3 (da) * 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
GB201205654D0 (en) 2012-03-29 2012-05-16 Syngenta Ltd Herbicidal compounds
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
WO2015050379A1 (ko) * 2013-10-01 2015-04-09 광주과학기술원 신규한 퀴놀리논 유도체 및 이의 용도
EP3067356B1 (en) 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN113260609A (zh) * 2018-09-04 2021-08-13 美真达治疗公司 芳烃受体拮抗剂及其使用方法

Also Published As

Publication number Publication date
CN118215654A (zh) 2024-06-18
JP2026009928A (ja) 2026-01-21
TW202328094A (zh) 2023-07-16
CA3231016A1 (en) 2023-03-16
KR20240056750A (ko) 2024-04-30
US12037322B2 (en) 2024-07-16
TWI829325B (zh) 2024-01-11
EP4402126A1 (en) 2024-07-24
AU2022342091A1 (en) 2024-03-21
JP2024531694A (ja) 2024-08-29
JP7748545B2 (ja) 2025-10-02
US20230127797A1 (en) 2023-04-27
MX2024003107A (es) 2024-04-05
WO2023039278A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
AR126963A1 (es) Agonistas de ahr
PE20230238A1 (es) Inhibidores de kras g12c
DE69529690D1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DE69617676D1 (de) Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2-inhibitoren
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
RU2018106453A (ru) Соединения
KR950005308A (ko) 직장투여용 조성물
DE60215699D1 (de) Quinolinone als prostaglandin rezeptor liganden
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
EA202191967A1 (ru) Замещенные полициклические карбоновые кислоты, их аналоги и способы их применения
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
PE20251600A1 (es) Compuestos que contienen heteroatomos y usos de estos
JP2019065009A5 (es)
MX2022011240A (es) Azálidos de urea inmunomoduladores.
AR123281A1 (es) Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
JPWO2022235558A5 (es)
PE20241726A1 (es) Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits
CO2025004701A2 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
AR127233A1 (es) Agonistas de ahr
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
PE20240585A1 (es) Compuestos pirimidinicos para usar como inhibidores de map4k1
RU2019104928A (ru) Производное индола, используемое в качестве ингибитора CRTH2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal